BTCC / BTCC Square / Global Cryptocurrency /
Recursion Pharmaceuticals (RXRX) Stock Surges After Beating Q4 Estimates

Recursion Pharmaceuticals (RXRX) Stock Surges After Beating Q4 Estimates

Published:
2026-02-25 17:38:02
16
1
BTCCSquare news:

Recursion Pharmaceuticals (RXRX) shares rallied sharply following a stronger-than-expected fourth-quarter performance. The AI-driven drug developer reported a loss of $0.21 per share, surpassing the consensus estimate of a $0.30 loss. Revenue soared to $35.54 million, far exceeding the $24.51 million forecast, fueled by a $30 million milestone payment from Roche.

Full-year revenue climbed 27% year-over-year to $74.7 million, bolstered by strategic acquisitions. With $743.3 million in cash reserves, the company maintains financial flexibility through 2028. The results underscore Recursion's growing traction in biopharma partnerships and AI-enabled drug discovery.

|Square

Get the BTCC app to start your crypto journey

Get started today Scan to join our 100M+ users

All articles reposted on this platform are sourced from public networks and are intended solely for the purpose of disseminating industry information. They do not represent any official stance of BTCC. All intellectual property rights belong to their original authors. If you believe any content infringes upon your rights or is suspected of copyright violation, please contact us at [email protected]. We will address the matter promptly and in accordance with applicable laws.BTCC makes no explicit or implied warranties regarding the accuracy, timeliness, or completeness of the republished information and assumes no direct or indirect liability for any consequences arising from reliance on such content. All materials are provided for industry research reference only and shall not be construed as investment, legal, or business advice. BTCC bears no legal responsibility for any actions taken based on the content provided herein.